Johnson & Johnson (JNJ) remains one of the world's largest and most diversified healthcare companies, operating through its Innovative Medicine and MedTech segments. The Innovative Medicine side focuses on pharmaceuticals in oncology, immunology, neuroscience, cardiovascular, and pulmonary hypertension, with key products like DARZALEX, TREMFYA, and CARVYKTI. MedTech covers surgical technologies, orthopaedics, cardiovascular devices, and vision care. I follow the stock for its reliable cash flows, long history of dividend increases, and efforts to lead in oncology while expanding into areas like robotic surgery.
Over the trailing 30 days, JNJ shares rose approximately 10.6%, moving from a close near $255.56 to about $282.77 at the latest available price. The path included some consolidation in mid-October before a stronger push in late October and November, reaching a record high near $282.03 in early November. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Over the broader trailing quarter, the stock gained roughly 7.8% from its mid-August level near $262.37. This advance reflects an improving growth story in pharmaceuticals, even with softer MedTech results and the one-time legal charge in the third-quarter report.
Several clear catalysts backed the move. In mid-October, Johnson & Johnson reported third-quarter worldwide sales of $25.4 billion, up about 5.9% year over year, with adjusted diluted EPS of $2.59. Management raised full-year 2026 guidance, with the midpoint of reported sales lifted to roughly $101.2 billion and adjusted diluted EPS to about $11.10. Investors focused on operational strength in oncology and immunology rather than the GAAP impact from the proposed talc litigation resolution.
In early November, the FDA granted accelerated approval to RYBREVANT FASPRO for adults with recurrent or metastatic head and neck squamous cell carcinoma, based on a 42% confirmed overall response rate in the OrigAMI-4 trial. This expanded the oncology franchise and supported higher trading volume along with the push to record highs. A quarterly dividend of $1.34 per share and broader interest in defensive healthcare names also helped sentiment.
The quarterly trend ties into a broader portfolio shift. Innovative Medicine delivered operational sales growth of 7.9% in the third quarter, driven by double-digit gains in oncology assets such as DARZALEX, CARVYKTI, and TECVAYLI, plus immunology and neuroscience products like TREMFYA and CAPLYTA. Newer launches, including ICOTYDE for psoriasis and INLEXZO for bladder cancer, added to the pipeline narrative.
These positives helped offset a MedTech segment that grew only 2.5% operationally and missed internal targets, with softness mainly in international markets and the Abiomed business. Regulatory progress, including FDA De Novo authorization for the OTTAVA robotic surgery system, supports the longer-term story behind the stock's climb.
Investors will monitor whether Innovative Medicine can maintain above-market growth as newer products help offset the loss of exclusivity on STELARA. MedTech recovery, especially in Abiomed and international surgery, remains a variable, along with the OTTAVA launch. Additional items include updates on the talc litigation resolution, the planned orthopaedics separation, and any 2027 guidance at the December Enterprise Business Review. Broader factors like U.S. drug-pricing reform also matter for the sector.
In my own research process, I occasionally turn to Tickeron’s AI Trading Bots to review automated strategies that align with names like JNJ. These tools scan thousands of tickers and highlight approaches with different timeframes and performance metrics, offering a data-driven way to complement fundamental analysis without replacing it.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
The 10-day moving average for JNJ crossed bullishly above the 50-day moving average on October 30, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 65%.
The Momentum Indicator moved above the 0 level on October 22, 2026. You may want to consider a long position or call options on JNJ as a result. In 42 of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 50%.
The Moving Average Convergence Divergence (MACD) for JNJ just turned positive on October 21, 2026. Looking at past instances where JNJ's MACD turned positive, the stock continued to rise in 25 of 47 cases over the following month. The odds of a continued upward trend are 53%.
JNJ moved above its 50-day moving average on October 26, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +1.90% 3-day Advance, the price is estimated to grow further. Considering data from situations where JNJ advanced for three days, in 165 of 355 cases, the price rose further within the following month. The odds of a continued upward trend are 46%.
The Aroon Indicator entered an Uptrend today. In 124 of 260 cases where JNJ Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 48%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where JNJ declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 43%.
JNJ broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Profit vs. Risk Rating rating for this company is 2 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 58, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 11 (best 1 - 100 worst), indicating outstanding price growth. JNJ’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 37 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 76 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.834) is normal, around the industry mean (-1.421). P/E Ratio (31.640) is within average values for comparable stocks, (21.700). Projected Growth (PEG Ratio) (2.852) is also within normal values, averaging (5.738). Dividend Yield (0.019) settles around the average of (0.038) among similar stocks. P/S Ratio (6.658) is also within normal values, averaging (4.033).
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
an investment holding company with interests in health care products
Industry PharmaceuticalsMajor